Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 3/20 | 0.45 |
| ▸ | CA1 | P00915 | 3/20 | 0.45 |
| ▸ | CA2 | P00918 | 3/20 | 0.45 |
| ▸ | CA9 | Q16790 | 3/20 | 0.45 |
| ▸ | MLYCD | O95822 | 2/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | CHRNB2 | P17787 | 2/20 | 0.31 |
| ▸ | CHRNA4 | P43681 | 2/20 | 0.31 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.30 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.30 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.30 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.30 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | FPR1 | P21462 | 1/20 | 0.30 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12987377 | 0.81 | CHRNB2 (0.36) | CA12CA1CA2CA9CHRNB2 | |
| SCHEMBL6895788 | 0.80 | CA12 (0.46) | CA12CA1CA2CA9MLYCD | |
| SCHEMBL10087929 | 0.80 | CA12 (0.46) | CA12CA1CA2CA9LMNA | |
| SCHEMBL304755 | 0.79 | CA12 (0.33) | CA12CA1CA2CA9 | |
| SCHEMBL304323 | 0.79 | MEN1 (0.32) | CA12CA1CA2CA9CHRNB2 | |
| SCHEMBL18856294 | 0.75 | CA12 (0.42) | CA12CA1CA2CA9MLYCD | |
| SCHEMBL4332616 | 0.75 | MEN1 (0.45) | CA12CA1CA9LMNACHRNB2 | |
| SCHEMBL306031 | 0.75 | CA12 (0.50) | CA12CA1CA2CA9MLYCD | |
| SCHEMBL19359952 | 0.74 | MAPT (0.41) | CA12CA1CA2CA9MLYCD | |
| SCHEMBL306030 | 0.73 | CA1 (0.48) | CA12CA1CA2CA9MLYCD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2903979-B1 | NOVEL COMPOUNDS, THEIR PREPARATION AND THEIR USES | INHIBIKASE THERAPEUTICS INC (US) | 2020-08-19 | — | — | EP | claimed |
| US-9487500-B2 | Compounds and compositions thereof | INHIBIKASE THERAPEUTICS, INC. (US) | 2016-11-08 | — | — | US | claimed |
| US-9359376-B2 | Substituted methylformyl reagents and method of using same to modify physicochemical and/or pharmacokinetic properties of compounds | SPHAERA PHARMA PTE. LTD (SG) | 2016-06-07 | — | — | US | claimed |
| EP-2903979-A1 | NOVEL COMPOUNDS, THEIR PREPARATION AND THEIR USES | Inhibikase Therapeutics, Inc. (US) | 2015-08-12 | — | — | EP | claimed |
| US-20140121367-A1 | SUBSTITUTED METHYLFORMYL REAGENTS AND METHOD OF USING SAME TO MODIFY PHYSICOCHEMICAL AND/OR PHARMACOKINETIC PROPERTIES OF COMPOUNDS | PIVOT HOLDING LLC | 2014-05-01 | — | — | US | claimed |
| US-20140100225-A1 | NOVEL COMPOUNDS, THEIR PREPARATION AND THEIR USES | INHIBIKASE THERAPEUTICS, INC. (US) | 2014-04-10 | — | — | US | claimed |
| WO-2014055938-A1 | NOVEL COMPOUNDS, THEIR PREPARATION AND THEIR USES | INHIBIKASE THERAPEUTICS, INC. (US) | 2014-04-10 | — | — | WO | claimed |
| CN-103607888-A | Substituted methyl formyl reagents and methods of using the same to improve physicochemical and/or pharmacokinetic properties of compounds | SPHAERA PHARMA PRIVATE LTD | 2014-02-26 | — | — | CN | claimed |
| EP-2693876-A1 | SUBSTITUTED METHYLFORMYL REAGENTS AND METHOD OF USING SAME TO MODIFY PHYSICOCHEMICAL AND/OR PHARMACOKINETIC PROPERTIES OF COMPOUNDS | Sphaera Pharma Pte. Ltd (SG) | 2014-02-12 | — | — | EP | claimed |
| WO-2012137225-A1 | SUBSTITUTED METHYLFORMYL REAGENTS AND METHOD OF USING SAME TO MODIFY PHYSICOCHEMICAL AND/OR PHARMACOKINETIC PROPERTIES OF COMPOUNDS | SPHAERA PHARMA PVT. LTD (IN) | 2012-10-11 | — | — | WO | claimed |
| US-12629371-B2 | Compositions and methods for inhibiting kinases | INHIBIKASE THERAPEUTICS, INC. (US) | 2026-05-19 | — | — | US | disclosed |
| CN-109608436-B | Substituted methyl formyl reagents and methods of using same to improve physicochemical and/or pharmacokinetic properties of compounds | 斯法尔制药私人有限公司 | 2022-10-11 | — | — | CN | disclosed |
| EP-2903979-B1 | NOVEL COMPOUNDS, THEIR PREPARATION AND THEIR USES | INHIBIKASE THERAPEUTICS INC (US) | 2020-08-19 | — | — | EP | disclosed |
| US-20200046699-A1 | COMPOSITIONS AND METHODS FOR INHIBITING KINASES | INHIBIKASE THERAPEUTICS, INC. | 2020-02-13 | — | — | US | disclosed |
| EP-3532066-A1 | COMPOSITIONS AND METHODS FOR INHIBITING KINASES | Inhibikase Therapeutics, Inc. (US) | 2019-09-04 | — | — | EP | disclosed |
| CN-101267815-A | metallo-beta-lactamase inhibitors | MEIJI SEIKA KAISHA (JP) | 2008-09-17 | — | — | CN | disclosed |
| EP-1941873-A1 | METALLO-BETA-LACTAMASE INHIBITOR | MEIJI SEIKA KAISHA LTD. (JP) | 2008-07-09 | — | — | EP | disclosed |
| US-20080090825-A1 | Metallo-beta-lactamase inhibitors | MEIJI SEIKA KAISHA, LTD. (JP) | 2008-04-17 | — | — | US | disclosed |
| EP-1870412-A1 | 2-THIOETHENYL CARBAPENEM DERIVATIVE | MEIJI SEIKA KAISHA LTD. (JP) | 2007-12-26 | — | — | EP | disclosed |
| US-20070004700-A1 | 2-Thioethenyl substituted carbapenem derivatives | MEIJI SEIKA KAISHA, LTD. (JP) | 2007-01-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080090825-A1 | Metallo-beta-lactamase inhibitors | ME1, MGAM, GAA | CA12 909/4885CA1 727/4885CA2 313/4885 |
| US-20140121367-A1 | SUBSTITUTED METHYLFORMYL REAGENTS AND METHOD OF USING SAME TO MODIFY PHYSICOCHEMICAL AND/OR PHARMACOKINETIC PROPERTIES OF COMPOUNDS | TPMT, BHMT2, PFAS | CA12 1866/4885CA1 2718/4885CA2 3448/4885 |
| US-20070004700-A1 | 2-Thioethenyl substituted carbapenem derivatives | MTAP, BLVRB, BPGM | CA12 799/4885CA1 3160/4885CA2 1641/4885 |
| US-12629371-B2 | Compositions and methods for inhibiting kinases | PTK2, HCK, PTK2B | CA12 2071/4885CA1 1694/4885CA2 446/4885 |
| US-20140100225-A1 | NOVEL COMPOUNDS, THEIR PREPARATION AND THEIR USES | POLI, MCL1, HRAS | CA12 2680/4885CA1 4406/4885CA2 4709/4885 |
| US-20200046699-A1 | COMPOSITIONS AND METHODS FOR INHIBITING KINASES | ABL1, FYN, PTK2 | CA12 4309/4885CA1 2927/4885CA2 2347/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.